Company intelligence / Profile preview

OREGA Biotech

Ecully, Auvergne-Rhone-Alpes, Franceorega-biotech.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

Their lead program, anti-CD39 antibody IPH5201, has been licensed to Innate Pharma and partnered with AstraZeneca. IPH5201 is now entering phase 2 trial in lung cancer[3].

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies
Industry: Biotech

Drug pipeline

1 asset

anti-IL-17B antibody

Preclinical

Partnerships

Innate Pharma (2016)AstraZeneca (2018)[3]

Beyond the preview

Go deeper on OREGA Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OREGA Biotech.

Explore the full profile